Explore the words cloud of the THERACAT project. It provides you a very rough idea of what is the project "THERACAT" about.
The following table provides information about the project.
FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
|Coordinator Country||Spain [ES]|
|Total cost||3˙383˙216 €|
|EC max contribution||3˙383˙216 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2018-03-01 to 2022-02-28|
Take a look of project's partnership.
|1||FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA||ES (BARCELONA)||coordinator||247˙872.00|
|2||TECHNISCHE UNIVERSITEIT EINDHOVEN||NL (EINDHOVEN)||participant||758˙603.00|
|3||THE UNIVERSITY OF EDINBURGH||UK (EDINBURGH)||participant||546˙575.00|
|4||TEL AVIV UNIVERSITY||IL (TEL AVIV)||participant||520˙601.00|
|5||BIOGELX LIMITED||UK (NEWHOUSE)||participant||273˙287.00|
|6||UNIVERSITAT BASEL||CH (BASEL)||participant||265˙226.00|
|7||TEVA PHARMACEUTICAL INDUSTRIES LIMITED||IL (PETACH TIVKA)||participant||260˙300.00|
|8||RIJKSUNIVERSITEIT GRONINGEN||NL (GRONINGEN)||participant||255˙374.00|
|9||TAGWORKS PHARMACEUTICALS BV||NL (Eindhoven)||participant||255˙374.00|
THERACAT is an international and multidisciplinary consortium aiming at the training of 13 ESRs on the innovative topic of novel bio-orthogonal catalysis-based tools for cancer therapy. This ETN comprises 6 academic partners, 3 industrial partners active in the pharmaceutical market (1 large pharmaceutical company, Teva, and 2 SMEs, BiogelX and Tagworks) and 3 partners with focus on science communication (Cancer research UK), gender and minorities (UAB-Observatory for Equality) and management and entrepreneurship (ESADE business school). The combination of academic, private and society-involved organisations will provide a broad training for the 13 ESRs recruited, equipping them with the necessary skills to succeed as scientists, industrial researchers and entrepreneurs. The development of novel cancer therapies is a major challenge for academic research and pharmaceutical industries. THERACAT aims to establish a training programme focused on the development of THERApeutic CATalysts. In this strategy, materials bearing a catalytic unit are delivered to the tumour and subsequently non-active prodrugs are administered. The prodrugs are non-toxic and therefore generate limited side effects. Only at the tumour site the catalytic particles convert the prodrugs into active compounds that generate a therapeutic effect. This approach presents several advantages on the classical drug delivery paradigm including limited side effects and prolonged efficacy. This multidisciplinary research programme will be the setting for the training of 13 ESRs. The combination of the research expertise, the cutting-edge facilities and the complementary skills present in the consortium holds a great promise for the advancement of their careers, as well as of the knowledge of catalysis-based anticancer therapies and the development of marketable technologies and products.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERACAT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "THERACAT" are provided by the European Opendata Portal: CORDIS opendata.
Big Data Challenges for MathematicsRead More
Training research pioneers by utilizing and validating the promise of electroporation for minimal invasive oncological treatments.Read More
The Future of European Independent Art Spaces in a Period of Socially Engaged ArtRead More